GlassScriptPhysician profile
Lenora Taylor
NPI 1619619178
$6,628.04
in general payments reported to CMS, 2019-2025
31 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $643 · 2023: $1,814 · 2024: $1,907 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,925 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,924.59 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.03 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $787.86 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $762.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $744.29 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.07 | 2022-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $402.22 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $400.21 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Astellas Pharma US INC | $292.96 | 2025 | Veozah |
| Amgen INC. | $194.01 | 2023-2025 | Otezla, Repatha, Otezla |
| Corium, LLC | $192.00 | 2023-2024 | Azstarys |
| Lundbeck LLC | $178.30 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $129.93 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $128.54 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $125.64 | 2022-2023 | Belsomra, Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $110.72 | 2023-2025 | Spravato, Xarelto |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $105.94 | 2023-2025 | |
| Exact Sciences Corporation | $100.24 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $72.26 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $71.40 | 2024 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $58.73 | 2022-2023 | |
| Abbott Laboratories | $51.59 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Dexcom, INC. | $42.84 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $33.04 | 2025 | |
| Sumitomo Pharma America, INC. | $23.76 | 2024 | Gemtesa |
| Eisai INC. | $23.50 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.49 | 2024 | Belbuca |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.85 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.56 | 2025 | Xifaxan |
| Harmony Biosciences LLC | $18.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.74 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $14.88 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenora Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.